Chimeric antigen receptor (CAR) T (CAR-T) cell transfer has made great success in
hematological malignancies, but only shown a limited effect on solid tumors. One of the …

CAR T cell qualities, such as persistence and functionality play important roles in
determining the outcome of cancer immunotherapy. In spite of full functionality, it has been …

Adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR) is deemed as
the silver bullet to overcome the barriers of solid tumor treatment; however, the therapeutic …

Chimeric antigen receptor (CAR) T cells demonstrate remarkable success in treating
hematological malignancies, but their effectiveness in non-hematopoietic cancers remains …

The potential for immunotherapy as a treatment option for cancer is clear from remarkable
responses of some leukemia patients to adoptive cell transfer using autologous T cells …

Patients who receive chimeric antigen receptor (CAR)–T cells that are enriched in memory T
cells exhibit better disease control as a result of increased expansion and persistence of the …

Adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated unparalleled
responses in hematologic cancers, yet antigen escape and tumor relapse occur frequently …

The adoptive transfer of chimeric antigen receptor-modified T (CAR-T) cells is a novel
cancer treatment that has led to encouraging breakthroughs in the treatment of …

Immunotherapy using chimeric-antigen receptor (CAR)-T cells is emerging as an exciting
therapeutic approach for cancer therapies. Autologous CAR-modified T cells targeting a …

Simple Summary The aging of the world population leads to a constant increase of cancer-
related morbidity and mortality. Treatment of late-stage tumors has become a significant …